Dr Mark Kris highlights a recent study on osimertinib in NSCLC and outlines the best approaches for treatment beyond progression.

Treatment landscape of EGFR-mutant non–small cell lung cancer has evolved in the most recent years. In the metastatic setting, with combination approaches tested in first-line, whereas in the ...

The risk for acute kidney injury was not higher among patients with an eGFR dip at empagliflozin initiation. Previous studies have reported renal benefits with sodium glucose cotransporter 2 inhibitor ...

Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...

EGFR tyrosine kinase inhibitors (TKIs) are effective treatments for EGFR-mutant non-small cell lung cancer (NSCLC). However, even after undergoing systemic therapy, patients may have oligometastatic ...

Please provide your email address to receive an email when new articles are posted on . Newer eGFR calculations that do not consider race show a link between kidney function and dementia. Equations ...

Please provide your email address to receive an email when new articles are posted on . SGLT2 inhibitors vs. other agents were tied to a slower eGFR decline for adults with ADPKD and type 2 diabetes.

Dr. Nicolas Girard discussed the current treatment options for patients with EGFR-mutant lung cancer, including emerging combination regimens. Current treatment options for EGFR-mutant lung cancer ...